Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15905447 | 0.91 | GAA (0.45) | MAPTMEN1KMT2AGAATSHR | |
| Hydrochloric Acid SCHEMBL15904893 | 0.91 | GAA (0.44) | MAPTMEN1KMT2AGAATSHR | |
| SCHEMBL15919263 | 0.90 | ESR1 (0.42) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL15919270 | 0.89 | ACACB (0.42) | MAPTMEN1KMT2AGAA | |
| SCHEMBL15919456 | 0.84 | POLB (0.53) | MAPTMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL15919473 | 0.81 | DHODH (0.42) | MAPTMEN1KMT2AGAATSHR | |
| SCHEMBL15919419 | 0.78 | ACACB (0.44) | MAPTMEN1KMT2AGAA | |
| SCHEMBL15919272 | 0.78 | PLA2G2A (0.46) | MAPTMEN1KMT2AGAATSHR | |
| SCHEMBL15905018 | 0.77 | ALDH1A1 (0.43) | MAPTMEN1KMT2AGAATSHR | |
| SCHEMBL15905083 | 0.76 | MAPT (0.48) | MAPTMEN1KMT2AGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | MAPT 2507/4885MEN1 511/4885KMT2A 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.